Journals / Retina-Vitreus / 2021 / Cilt: 30 - Sayı: 2

Intravitreal Dexamethasone Implant Treatment in Patients With Diabetic Macular Edema Resistant to Anti-VEGF Treatment

Pages
152–157
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A significant improvement was observed in BCVA while a significant decrease in CMT at all time points when compared to baseline (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the efficacy and safety of intravitreal dexamethasone implant (IDI) (OZURDEX) in the patients with diabetic macular edema (DME) resistant to anti-VEGF treatment.
📊
Key Findings & Data:Study Design: This retrospective study included 93 eyes of 93 patients who underwent IDI injection and changes in best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP) as well as presence of DME and ocular side effects were investigated.
💡
Conclusion & Impact:A significant improvement was observed in BCVA while a significant decrease in CMT at all time points when compared to baseline (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the efficacy and safety of intravitreal dexamethasone implant (IDI) (OZURDEX) in the patients with diabetic macular edema (DME) resistant to anti-VEGF treatment. Study Design: This retrospective study included 93 eyes of 93 patients who underwent IDI injection and changes in best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP) as well as presence of DME and ocular side effects were investigated. Results: Ninety three eyes of 93 patients (45 male, 48 female; the mean age was 67.32±10.68 years) were included. At least five monthly intravitreal ranibizumab (Lucentis) injections were administered before IDI and patients were considered to have resistant DME. A significant improvement was observed in BCVA while a significant decrease in CMT at all time points when compared to baseline (p

🔖

Cite This Article

USLU, H., KANRA, A. Y., ALTINEL, M. G. (2022). Intravitreal Dexamethasone Implant Treatment in Patients With Diabetic Macular Edema Resistant to Anti-VEGF Treatment. Retina-Vitreus, Cilt: 30 - Sayı: 2, 152–157. https://ajindex.com/articles/589069

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74
  2. He Y, Ren XJ, Hu BJ, et al. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmology 2018;18:121 3. Cheung N, Wong IY, Wong TY. Ocular anti- VEGF therapy for diabetic retinopathy: over-view of clinical efficacy and evolving applications. Diabetes Care 2014;37: 900-5
  3. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119:789-801
  4. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46:1440-4
  5. Massin P, Bandello F, Garweg JG, et al. Safety and ef ficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399-405
  6. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013-22
  7. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-51
  8. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130:972-9
  9. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015;122:2044-52
  10. Sim DA, Keane PA, Tufail A, et al. Automated retinal image analysis for diabetic retinopathy in telemedicine. Curr Diab Rep. 2015;15:14
  11. Stein JD, Newman-Casey PA, Kim DD, et al. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology 2013;120(9):1835-42
  12. Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-13
  13. Elman MJ, Bressler NM, Qin H, et al. Diabetic Retinopathy Clinical Re